THL Credit, Inc. TCRX 深 滬
等待開盤 09-10 09:30:00 美东时间
1.84
-0.040
-2.13%
華盛通- 最 高1.92
- 今 開1.90
- 成交量 19.61万股
- 最 低 1.81
- 昨 收 1.88
- 總市值 1.04亿
- 52周最高 6.225
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.02
- 委 比 -73.67%
- 總股本 5674.80万
- 歷史最高 14.71
- 量 比 1.03
- 振 幅 5.85%
- 歷史最低 1.02
- 每 手 1
- 風險率 1.51%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多TScan Therapeutics to Participate in Upcoming Investor Conferences
<p>TScan Therapeutics announced participation in upcoming investor conferences: the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept. 9 and the H.C. Wainwright 27th Annual Global Investment Conference on Sept. 10. Webcasts will be available on the company's website, ir.tscan.com, with replays accessible for 90 days. TScan focuses on developing TCR-engineered T cell therapies for cancer treatment.</p><br>
09-03 11:00
TScan Therapeutics Q2 EPS $(0.28), Inline, Sales $3.076M Beat $1.405M Estimate
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.28) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $3.076
08-12 19:12
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
TScan Therapeutics reported Q2 2025 financial results, including revenue of $3.1 million, R&D expenses of $32.6 million, and a net loss of $37.0 million. The company announced plans to treat first solid tumor patients with multiplex TCR-T therapy in Q3 2025 and expects to present two-year relapse data from the ALLOHA™ Phase 1 trial by year-end. Cash reserves of $218 million are sufficient to fund operations into Q1 2027.
08-12 11:00
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
TScan Therapeutics, Inc. will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 4:55 p.m. ET in New York. A webcast will be available on the company’s website, ir.tscan.com, with an archived replay for 90 days. TScan is a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment. The company is currently enrolling patients in two clinical programs: ALLOHA™ for hematologic malignancies a...
05-28 11:00
美股大行评级 | 潜在涨幅105.34%！Amylyx Pharmaceuticals获Leerink Partners升目标价至10美元，上调至"跑赢大市"评级
每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。
05-08 08:45
HC Wainwright & Co. Maintains Buy on TScan Therapeutics, Lowers Price Target to $10
HC Wainwright & Co. analyst Andres Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $15 to $10.
05-07 20:26
TScan Therapeutics GAAP EPS of $0.26
TScan Therapeutics press release (NASDAQ:TCRX): Q1 GAAP EPS of $0.26. Revenue of $2.2M beats by $1.12M. More on TScan Therapeutics TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025 TScan Ther...
05-06 23:13
美股大行评级 | 潜在涨幅147.43%！HC Wainwright & Co.上调Pacira BioSciences目标价至65美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1116650478822592513.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Pacira BioSciences(PCRX)"买入"评级，目标价从48美元升至65美元</p> <p>• 瑞穗：上调Amylyx Pharmaceuticals(AM
04-09 08:50
Needham Reiterates Buy on TScan Therapeutics, Maintains $9 Price Target
Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $9 price target.
04-08 20:46
美股大行评级 | 美银证券：维持AerCap Holdings"买入"评级，目标价从105美元升至125美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1105190809351499777.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• RBC Capital：维持Canadian Natural Res(CNQ)"跑赢大市"评级，目标价从62美元升至63美元</p> <p>• 摩根大通：维持Carvana(CVNA)"超配"评级，目标价从350美元升至3
03-10 10:29
